HRP20100194T1 - Perikondenzirani triciklički spojevi, korisni kao antibakterijska sredstva - Google Patents
Perikondenzirani triciklički spojevi, korisni kao antibakterijska sredstva Download PDFInfo
- Publication number
- HRP20100194T1 HRP20100194T1 HR20100194T HRP20100194T HRP20100194T1 HR P20100194 T1 HRP20100194 T1 HR P20100194T1 HR 20100194 T HR20100194 T HR 20100194T HR P20100194 T HRP20100194 T HR P20100194T HR P20100194 T1 HRP20100194 T1 HR P20100194T1
- Authority
- HR
- Croatia
- Prior art keywords
- dihydro
- methyl
- amino
- pyrrolo
- quinolin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 25
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 41
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 19
- 239000001257 hydrogen Substances 0.000 claims abstract 19
- 125000006574 non-aromatic ring group Chemical group 0.000 claims abstract 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 11
- 125000003118 aryl group Chemical group 0.000 claims abstract 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract 8
- 150000002367 halogens Chemical group 0.000 claims abstract 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 8
- 101150020251 NR13 gene Proteins 0.000 claims abstract 7
- 101000585507 Solanum tuberosum Cytochrome b-c1 complex subunit 7 Proteins 0.000 claims abstract 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract 6
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 6
- 125000003277 amino group Chemical group 0.000 claims abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 6
- 125000004429 atom Chemical group 0.000 claims abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 5
- 125000005842 heteroatom Chemical group 0.000 claims abstract 5
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 125000005647 linker group Chemical group 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000012453 solvate Substances 0.000 claims abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims abstract 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 2
- KSOVGRCOLZZTPF-QMKUDKLTSA-N (1s,2s,3r,4r)-3-[[5-fluoro-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(C(=CN=1)F)=NC=1NC(C=C1C)=CC=C1N1CCN(C)CC1 KSOVGRCOLZZTPF-QMKUDKLTSA-N 0.000 claims 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 15
- -1 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl Chemical group 0.000 claims 5
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- SRICOHRDRMZREQ-UHFFFAOYSA-N 1-({4-[(6,7-dihydro[1,4]dioxino[2,3-c]pyridazin-3-ylmethyl)amino]-1-piperidinyl}methyl)-9-fluoro-1,2-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-4-one Chemical group O1CCOC(N=N2)=C1C=C2CNC(CC1)CCN1CC1CN2C(=O)C=CC3=CC=C(F)C1=C32 SRICOHRDRMZREQ-UHFFFAOYSA-N 0.000 claims 2
- BORVGJDOTIRNBW-UHFFFAOYSA-N 1-[(4-amino-1-piperidinyl)methyl]-9-fluoro-1,2-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-4-one Chemical compound C1CC(N)CCN1CC1C(C(F)=CC=C2C=CC3=O)=C2N3C1 BORVGJDOTIRNBW-UHFFFAOYSA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 2
- MQNSSUSIYXBURE-UHFFFAOYSA-N 1-({4-[(6,7-dihydro-5h-pyrano[2,3-c]pyridazin-3-ylmethyl)amino]-1-piperidinyl}methyl)-9-fluoro-1-hydroxy-1,2-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-4-one Chemical compound FC1=CC=C2C=CC(=O)N3CC(O)(CN4CCC(CC4)NCC=4N=NC=5OCCCC=5C=4)C1=C23 MQNSSUSIYXBURE-UHFFFAOYSA-N 0.000 claims 1
- FZLZOUPODGQLNT-UHFFFAOYSA-N 1-({4-amino-1-piperidinyl}methyl)-9-(methyloxy)-1,2-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-4-one Chemical compound C12=C3C(OC)=CC=C2C=CC(=O)N1CC3CN1CCC(N)CC1 FZLZOUPODGQLNT-UHFFFAOYSA-N 0.000 claims 1
- IFKRFNMBFSYYDY-UHFFFAOYSA-N 1-[(4-amino-1-piperidinyl)methyl]-1,2-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-4-one Chemical compound C1CC(N)CCN1CC1C(C=CC=C2C=CC3=O)=C2N3C1 IFKRFNMBFSYYDY-UHFFFAOYSA-N 0.000 claims 1
- YHHXXECHEBPQBP-UHFFFAOYSA-N 1-[(4-amino-1-piperidinyl)methyl]-4-oxo-1,2-dihydro-4h-pyrrolo[3,2,1-ij]quinoline-9-carbonitrile Chemical compound C1CC(N)CCN1CC1C(C(=CC=C2C=CC3=O)C#N)=C2N3C1 YHHXXECHEBPQBP-UHFFFAOYSA-N 0.000 claims 1
- VHYAOGLIYAVOEE-UHFFFAOYSA-N 1-[(4-amino-1-piperidinyl)methyl]-9-fluoro-1-hydroxy-1,2-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-4-one Chemical compound C1CC(N)CCN1CC1(O)C(C(F)=CC=C2C=CC3=O)=C2N3C1 VHYAOGLIYAVOEE-UHFFFAOYSA-N 0.000 claims 1
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 claims 1
- MQFHHYRHAGYGMU-YRCPPYQGSA-N 3-[[(3R,4S)-4-(2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazin-7-ylmethylamino)-3-hydroxypiperidin-1-yl]methyl]-5-fluoro-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound N1CCOC(C=N2)=C1C=C2CN[C@H]1CCN(CC2C3=C4N(C(C=CC4=CC=C3F)=O)C2)C[C@H]1O MQFHHYRHAGYGMU-YRCPPYQGSA-N 0.000 claims 1
- JVNWVUOHULTYHD-GLTUQPQBSA-N 3-[[(3R,4S)-4-(2,3-dihydrofuro[2,3-c]pyridin-5-ylmethylamino)-3-hydroxypiperidin-1-yl]methyl]-5-fluoro-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound N([C@H]1CCN(CC2C3=C4N(C(C=CC4=CC=C3F)=O)C2)C[C@H]1O)CC(N=C1)=CC2=C1OCC2 JVNWVUOHULTYHD-GLTUQPQBSA-N 0.000 claims 1
- LOUOAXYWHCWZCD-UHFFFAOYSA-N 3-[[4-(1,2,3-benzothiadiazol-5-ylmethylamino)piperidin-1-yl]methyl]-5-fluoro-3-hydroxy-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound FC1=CC=C2C=CC(=O)N3CC(O)(CN4CCC(CC4)NCC=4C=C5N=NSC5=CC=4)C1=C23 LOUOAXYWHCWZCD-UHFFFAOYSA-N 0.000 claims 1
- RROSWNYOHNQETQ-UHFFFAOYSA-N 3-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound C1CCOC(C=N2)=C1C=C2CNC(CC1)CCN1CC1C(C=CC=C2C=CC3=O)=C2N3C1 RROSWNYOHNQETQ-UHFFFAOYSA-N 0.000 claims 1
- SQHKOUDUEHBDIK-UHFFFAOYSA-N 3-[[4-(5,6-dihydrofuro[2,3-c]pyridazin-3-ylmethylamino)piperidin-1-yl]methyl]-5-fluoro-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound C12=C3C(F)=CC=C2C=CC(=O)N1CC3CN(CC1)CCC1NCC(N=N1)=CC2=C1OCC2 SQHKOUDUEHBDIK-UHFFFAOYSA-N 0.000 claims 1
- KVGQSBRIOBDSPI-UHFFFAOYSA-N 3-[[4-(5,6-dihydrofuro[2,3-c]pyridazin-3-ylmethylamino)piperidin-1-yl]methyl]-5-fluoro-3-hydroxy-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound FC1=CC=C2C=CC(=O)N3CC(O)(CN4CCC(CC4)NCC=4N=NC=5OCCC=5C=4)C1=C23 KVGQSBRIOBDSPI-UHFFFAOYSA-N 0.000 claims 1
- PPTSVYCFNJYAOX-UHFFFAOYSA-N 3-[[4-(6,7-dihydro-5H-pyrano[2,3-c]pyridazin-3-ylmethylamino)piperidin-1-yl]methyl]-11-oxo-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraene-5-carbonitrile Chemical compound C1CCOC(N=N2)=C1C=C2CNC(CC1)CCN1CC1C(C(C#N)=CC=C2C=CC3=O)=C2N3C1 PPTSVYCFNJYAOX-UHFFFAOYSA-N 0.000 claims 1
- CGUDMPHYSVIHTA-UHFFFAOYSA-N 3-[[4-(6,7-dihydro-5H-pyrano[2,3-c]pyridazin-3-ylmethylamino)piperidin-1-yl]methyl]-5-fluoro-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound C1CCOC(N=N2)=C1C=C2CNC(CC1)CCN1CC1CN2C(=O)C=CC3=CC=C(F)C1=C32 CGUDMPHYSVIHTA-UHFFFAOYSA-N 0.000 claims 1
- GFKAPZJUJIITMX-UHFFFAOYSA-N 3-[[4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound C1N(C2=3)C(=O)C=CC2=CC=CC=3C1CN(CC1)CCC1NCC(N=C1)=CC2=C1OCS2 GFKAPZJUJIITMX-UHFFFAOYSA-N 0.000 claims 1
- ALBRFCMKVKVWLD-DEGSQWPTSA-N 3-[[[(3R,4S)-1-[(5-fluoro-11-oxo-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-3-yl)methyl]-3-hydroxypiperidin-4-yl]amino]methyl]-5H-pyridazino[3,4-b][1,4]thiazin-6-one Chemical compound N1C(=O)CSC(N=N2)=C1C=C2CN[C@H]1CCN(CC2C3=C4N(C(C=CC4=CC=C3F)=O)C2)C[C@H]1O ALBRFCMKVKVWLD-DEGSQWPTSA-N 0.000 claims 1
- WYVLOGFDMXFKKC-UHFFFAOYSA-N 3-[[[1-[(5-fluoro-11-oxo-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-3-yl)methyl]piperidin-4-yl]amino]methyl]-5H-pyridazino[3,4-b][1,4]thiazin-6-one Chemical compound N1C(=O)CSC(N=N2)=C1C=C2CNC(CC1)CCN1CC1CN2C(=O)C=CC3=CC=C(F)C1=C32 WYVLOGFDMXFKKC-UHFFFAOYSA-N 0.000 claims 1
- RUONPUREVAIOHW-LDCVWXEPSA-N 5-fluoro-3-[[(3R)-3-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)methyl]pyrrolidin-1-yl]methyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound C([C@H]1CCN(C1)CC1CN2C(=O)C=CC3=CC=C(C1=C32)F)NCC(N=C1)=CC2=C1OCS2 RUONPUREVAIOHW-LDCVWXEPSA-N 0.000 claims 1
- RWLLBVHVNZDSRK-AOWWOYQVSA-N 5-fluoro-3-[[(3R,4S)-3-hydroxy-4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound N([C@H]1CCN(CC2C3=C4N(C(C=CC4=CC=C3F)=O)C2)C[C@H]1O)CC(N=C1)=CC2=C1OCS2 RWLLBVHVNZDSRK-AOWWOYQVSA-N 0.000 claims 1
- WQNNEYOELAXMMF-GLTUQPQBSA-N 5-fluoro-3-[[(3R,4S)-3-hydroxy-4-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-2-yl)methylamino]piperidin-1-yl]methyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound C1CC(=O)N=C2NC(CN[C@H]3CCN(CC4C5=C6N(C(C=CC6=CC=C5F)=O)C4)C[C@H]3O)=CC=C21 WQNNEYOELAXMMF-GLTUQPQBSA-N 0.000 claims 1
- RUONPUREVAIOHW-UHFFFAOYSA-N 5-fluoro-3-[[3-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)methyl]pyrrolidin-1-yl]methyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound C12=C3C(F)=CC=C2C=CC(=O)N1CC3CN(C1)CCC1CNCC(N=C1)=CC2=C1OCS2 RUONPUREVAIOHW-UHFFFAOYSA-N 0.000 claims 1
- HJDMGFLBWSFREJ-UHFFFAOYSA-N 5-fluoro-3-[[4-[(5-oxo-2,3-dihydro-1H-indolizin-7-yl)methylamino]piperidin-1-yl]methyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-11-one Chemical compound C1=C2CCCN2C(=O)C=C1CNC(CC1)CCN1CC1CN2C(=O)C=CC3=CC=C(F)C1=C32 HJDMGFLBWSFREJ-UHFFFAOYSA-N 0.000 claims 1
- GSBNHPMPEBPESH-UHFFFAOYSA-N 6,7-dihydro-[1,4]dioxino[2,3-c]pyridazine Chemical compound N1=CC=C2OCCOC2=N1 GSBNHPMPEBPESH-UHFFFAOYSA-N 0.000 claims 1
- CAZNYHXZJYLYJA-UHFFFAOYSA-N 6,7-dihydro-[1,4]dioxino[2,3-c]pyridazine-3-carbaldehyde Chemical compound O1CCOC2=C1C=C(C=O)N=N2 CAZNYHXZJYLYJA-UHFFFAOYSA-N 0.000 claims 1
- FWGPRCPPGDVQRQ-UHFFFAOYSA-N 6-[[[1-[(11-oxo-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-3-yl)methyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]thiazin-3-one Chemical compound C12=C3C=CC=C2C=CC(=O)N1CC3CN(CC1)CCC1NCC1=CC=C2SCC(=O)NC2=N1 FWGPRCPPGDVQRQ-UHFFFAOYSA-N 0.000 claims 1
- CACMIOAHNFMYTI-UHFFFAOYSA-N 6-[[[1-[(5-fluoro-11-oxo-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-3-yl)methyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound O1CC(=O)NC2=NC(CNC3CCN(CC3)CC3CN4C(=O)C=CC5=CC=C(C3=C54)F)=CC=C21 CACMIOAHNFMYTI-UHFFFAOYSA-N 0.000 claims 1
- JMZNIUXCLOTTOS-UHFFFAOYSA-N 6-[[[1-[(5-fluoro-11-oxo-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-3-yl)methyl]pyrrolidin-3-yl]methylamino]methyl]-4H-pyrido[3,2-b][1,4]thiazin-3-one Chemical compound S1CC(=O)NC2=NC(CNCC3CCN(C3)CC3CN4C(=O)C=CC5=CC=C(C3=C54)F)=CC=C21 JMZNIUXCLOTTOS-UHFFFAOYSA-N 0.000 claims 1
- JYMILZBXODPWMC-IURRXHLWSA-N 7-chloro-6-[[[(3R)-1-[(5-fluoro-11-oxo-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-3-yl)methyl]pyrrolidin-3-yl]methylamino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1C(=O)COC(C=C2Cl)=C1N=C2CNC[C@H](C1)CCN1CC1CN2C(=O)C=CC3=CC=C(F)C1=C32 JYMILZBXODPWMC-IURRXHLWSA-N 0.000 claims 1
- UBGKEAUOEJPOTF-UHFFFAOYSA-N 7-chloro-6-[[[1-[(5-fluoro-11-oxo-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-3-yl)methyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1C(=O)COC(C=C2Cl)=C1N=C2CNC(CC1)CCN1CC1CN2C(=O)C=CC3=CC=C(F)C1=C32 UBGKEAUOEJPOTF-UHFFFAOYSA-N 0.000 claims 1
- JYMILZBXODPWMC-UHFFFAOYSA-N 7-chloro-6-[[[1-[(5-fluoro-11-oxo-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12),9-tetraen-3-yl)methyl]pyrrolidin-3-yl]methylamino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound N1C(=O)COC(C=C2Cl)=C1N=C2CNCC(C1)CCN1CC1CN2C(=O)C=CC3=CC=C(F)C1=C32 JYMILZBXODPWMC-UHFFFAOYSA-N 0.000 claims 1
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 1
- 241000588697 Enterobacter cloacae Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000588915 Klebsiella aerogenes Species 0.000 claims 1
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 1
- 241000589242 Legionella pneumophila Species 0.000 claims 1
- 241000588655 Moraxella catarrhalis Species 0.000 claims 1
- 241000588770 Proteus mirabilis Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 229940092559 enterobacter aerogenes Drugs 0.000 claims 1
- 229940032049 enterococcus faecalis Drugs 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 229940115932 legionella pneumophila Drugs 0.000 claims 1
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical compound COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 claims 1
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 150000004684 trihydrates Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol i/ili solvat: naznačen time što: R1a i R1b se neovisno bira između vodika; halogena; cijano; (C1-6)alkila; (C1-6)alkiltio; trifluormetila; trifluormetoksi; karboksi; hidroksi, izborno supstitutuiranog s (C1-6)alkilom ili (C1-6)alkoksi-supstitutuiranim (C1-6)alkilom; (C1-6)alkoksi-supstitutuirani (C1-6)alkil; hidroksi (C1-6)alkil; amino skupina, izborno N-supstitutuirana s jednom ili dvije (C1-6)alkilne, formilne, (C1-6)alkilkarbonilne ili (C1-6)alkilsulfonilne skupine; ili aminokarbonil, gdje amino skupina je izborno supstitutuirana s (C1-4)alkilom; R2 je vodik ili (C1-4)alkil, ili zajedno s R6 tvori Y, kao što je definirano niže; A je skupina (ia) ili (ib): u kojoj R3 je kao što je definirano za R1a ili R1b, ili je okso, a n je 1 ili 2; ili A je skupina (ii) u kojojW1, W2 i W3 su CR4R8;ili W2 i W3 su CR4R8, a W1 predstavlja vezu između W3 i N; X je O, CR4R8 ili NR6;jedan R4 je kao što je definirano za R1a i R1b, a ostatak i R8 su vodici ili jedan R4 i R8 su zajedno okso, a ostatak su vodici, R6 je vodik ili (C1-6)alkil, ili zajedno R2 tvori Y; R7 je vodik; halogen; hidroksi, izborno supstitutuiran s (C1-6)alkilom; ili (C1-6)alkil; Y je CR4R8CH2; CH2CR4R8; (C=O); CR4R8; CR4R8(C=O); ili (C=O)CR4R8;ili kada X je CR4R8, R8 i R7 zajedno predstavljaju vezu, U se bira između CO i CH2;R5 je izborno supstitutuirani biciklički karbociklički ili heterociklički prstenasti sustav (B) koji sadrži do četiri heteroatoma u svakom prstenu, gdjenajmanje jedan od prstena (a) i (b) je aromatski; X1 je C ili N kada je dio aromatskog ring, ili CR14 kada je dio nearomatskog prstena; X2 je N, NR13, O, S(O)x, CO ili CR14 kada je dio aromatskog ili nearomatskog prstena ili uz to može biti CR14R15 kada je dio nearomatskog prstena; X3 i X5 su neovisno N ili C; Y1 je 0- do 4-atomska vezna skupina, čiji se svaki atom neovisno bira između N, NR13, O, S(O)x, CO i CR14 kada je dio aromatskog ili nearomatskog prstena ili uz to može biti CR14R15 kada je dio nearomatskog prstena; Y2 je 2- do 6-atomska vezna skupina, gdje se svaki atom u Y2 being neovisno bira između N, NR13, O, S(O)x, CO, CR14 kada je dio aromatskog ili nearomatskog prstena ili uz to može biti CR14R15 kada je dio nearomatskog prstena; svakog od R14 i R15 se neovisno bira između: H; (C1-4)alkiltio; halogena; karboksi(C1-4)alkila; (C1-4)alkila; (C1-4)alkoksikarbonila; (C1-4)alkilkarbonila; (C1-4)alkoksi(C1-4)alkila; hidroksi; hidroksi(C1-4)alkila; (C1-4)alkoksi; nitro; cijano; karboksi; amino ili aminokarbonila, izborno mono- ili disupstitutuiranih s (C1-4)alkilom; ili R14 i R15 mogu zajedno predstavljati okso; svaki R13 je neovisno H; trifluormetil; (C1-4)alkil, izborno supstitutuiran s hidroksi, (C1-6)alkoksi, (C1-6)alkiltio, halogenom ili trifluormetilom; (C2-4)alkenil; (C1-4)alkoksikarbonil; (C1-4)alkilkarbonil; (C1-6)alkil-sulfonil; ili aminokarbonil, gdje amino skupina je izborno mono- ili disupstitutuirana s (C1-4)alkilom; svaki x je neovisno 0, 1 ili
Claims (23)
1. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol i/ili solvat:
[image]
naznačen time što:
R1a i R1b se neovisno bira između vodika; halogena; cijano; (C1-6)alkila; (C1-6)alkiltio; trifluormetila; trifluormetoksi; karboksi; hidroksi, izborno supstitutuiranog s (C1-6)alkilom ili (C1-6)alkoksi-supstitutuiranim (C1-6)alkilom; (C1-6)alkoksi-supstitutuirani (C1-6)alkil; hidroksi (C1-6)alkil; amino skupina, izborno N-supstitutuirana s jednom ili dvije (C1-6)alkilne, formilne, (C1-6)alkilkarbonilne ili (C1-6)alkilsulfonilne skupine; ili aminokarbonil, gdje amino skupina je izborno supstitutuirana s (C1-4)alkilom;
R2 je vodik ili (C1-4)alkil, ili zajedno s R6 tvori Y, kao što je definirano niže;
A je skupina (ia) ili (ib):
[image]
u kojoj R3 je kao što je definirano za R1a ili R1b, ili je okso, a n je 1 ili 2;
ili A je skupina (ii)
[image]
u kojoj
W1, W2 i W3 su CR4R8;
ili W2 i W3 su CR4R8, a W1 predstavlja vezu između W3 i N;
X je O, CR4R8 ili NR6;
jedan R4 je kao što je definirano za R1a i R1b, a ostatak i R8 su vodici ili jedan R4 i R8 su zajedno okso, a ostatak su vodici,
R6 je vodik ili (C1-6)alkil, ili zajedno R2 tvori Y;
R7 je vodik; halogen; hidroksi, izborno supstitutuiran s (C1-6)alkilom; ili (C1-6)alkil;
Y je CR4R8CH2; CH2CR4R8; (C=O); CR4R8; CR4R8(C=O); ili (C=O)CR4R8;
ili kada X je CR4R8, R8 i R7 zajedno predstavljaju vezu,
U se bira između CO i CH2;
R5 je izborno supstitutuirani biciklički karbociklički ili heterociklički prstenasti sustav (B)
[image]
koji sadrži do četiri heteroatoma u svakom prstenu, gdje
najmanje jedan od prstena (a) i (b) je aromatski;
X1 je C ili N kada je dio aromatskog ring, ili CR14 kada je dio nearomatskog prstena;
X2 je N, NR13, O, S(O)x, CO ili CR14 kada je dio aromatskog ili nearomatskog prstena ili uz to može biti CR14R15 kada je dio nearomatskog prstena;
X3 i X5 su neovisno N ili C;
Y1 je 0- do 4-atomska vezna skupina, čiji se svaki atom neovisno bira između N, NR13, O, S(O)x, CO i CR14 kada je dio aromatskog ili nearomatskog prstena ili uz to može biti CR14R15 kada je dio nearomatskog prstena;
Y2 je 2- do 6-atomska vezna skupina, gdje se svaki atom u Y2 being neovisno bira između N, NR13, O, S(O)x, CO, CR14 kada je dio aromatskog ili nearomatskog prstena ili uz to može biti CR14R15 kada je dio nearomatskog prstena;
svakog od R14 i R15 se neovisno bira između: H; (C1-4)alkiltio; halogena; karboksi(C1-4)alkila; (C1-4)alkila; (C1-4)alkoksikarbonila; (C1-4)alkilkarbonila; (C1-4)alkoksi(C1-4)alkila; hidroksi; hidroksi(C1-4)alkila; (C1-4)alkoksi; nitro; cijano; karboksi; amino ili aminokarbonila, izborno mono- ili disupstitutuiranih s (C1-4)alkilom; ili R14 i R15 mogu zajedno predstavljati okso;
svaki R13 je neovisno H; trifluormetil; (C1-4)alkil, izborno supstitutuiran s hidroksi, (C1-6)alkoksi, (C1-6)alkiltio, halogenom ili trifluormetilom; (C2-4)alkenil; (C1-4)alkoksikarbonil; (C1-4)alkilkarbonil; (C1-6)alkil-sulfonil; ili aminokarbonil, gdje amino skupina je izborno mono- ili disupstitutuirana s (C1-4)alkilom;
svaki x je neovisno 0, 1 ili 2; te
R9 je vodik ili hidroksi.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1a je metoksi, fluor ili cijano, a R1b je vodik.
3. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što R2 je vodik.
4. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što R9 je vodik.
5. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što A je skupina (ia), u kojoj n je 1, a R3 je vodik ili hidroksi.
6. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 4, naznačen time što A je (ii), W1 je veza, svaki od X, W2 i W3 je CH2, a R7 je H.
7. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što U je CH2.
8. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što R5 je aromatski heterociklički prsten (B), s 8-11 atoma u prstenu, uključujući 2-4 heteroatoma, od kojih najmanje jedan je N ili NR13, gdje Y2 sadrži 2-3 heteroatoma, od kojih je jedan S, a 1-2 su N, gdje je jedan N vezan na X3, ili heterociklički prsten (B) ima aromatski prsten (a), kojeg se bira između izborno supstitutuiranog benzo, pirido i piridazino, i nearomatski prsten (b), a Y2 ima 3-5 atoma, uključujući najmanje jedan heteroatom, gdje je O, S, CH2 ili NR13 vezan na X5, gdje R13 nije vodik, te bilo je NHCO vezan preko N na X3, ili je O, S, CH2 ili NH vezan na X3.
9. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 7, naznačen time što R5 se bira između:
3-okso-3,4-dihidro-2H-pirido[3,2-b][1,4]oksazin-6-ila;
3-okso-3,4-dihidro-2H-pirido[3,2-b][1,4]tiazin-6-ila;
6,7-dihidro[1,4]dioksino[2,3-c]piridazin-3-ila;
6,7-dihidro[1,4]oksatiino[2,3-c]piridazin-3-ila;
6,7-dihidro[1,4]oksatiino[3,2-c]piridazin-3-ila;
2,3-dihidro[1,4]dioksino[2,3-c]piridin-7-ila; te
[1,3]oksatiolo[5,4-c]piridin-6-ila.
10. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između:
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E2;
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({(3R,4S)-4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-3-hidroksi-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Dijastereomera 1;
1-({(3R,4S)-4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-3-hidroksi-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Dijastereomera 2;
9-Fluor-1-({(3R,4S)-3-hidroksi-4-[([1,3]oksatiolo[5,4-c]piridin-6-ilmetil)amino]-1-piperidinil}metil)-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
9-Fluor-1-[((3R,4S)-3-hidroksi-4-{[(6-okso-6,7-dihidro-5H-piridazino[3,4-b][1,4]tiazin-3-il)metil]amino)-1-piperidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({(3R,4S)-4-[(2,3-Dihidro-1H-pirido[3,4-b][1,4]oksazin-7-ilmetil)amino]-3-hidroksi-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({(3R,4S)-4-[(2,3-Dihidrofuro[2,3-c]piridin-5-ilmetil)amino]-3-hidroksi-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
9-Fluor-1-[((3R,4S)-3-hidroksi-4-{[(7-okso-1,5,6,7-tetrahidro-1,8-naftiridin-2-il)metil]amino)-1-piperidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(6,7-Dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E2;
9-Fluor-1-[(4-{[(3-okso-3,4-dihidro-2H-pirido[3,2-b][1,4]oksazin-6-il)metil]amino)-1-piperidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({4-[(2,3-dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-4-okso-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-9-karbonitrila, Enantiomera E1;
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E2;
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(2,3-Dihidro[1,4]oksatiino[2,3-c]piridin-7-ilmetil)amino]piperidin-1-il}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
9-Fluor-1-hidroksi-1-[(4-{[(3-okso-3,4-dihidro-2H-pirido[3,2-6][1,4]oksazin-6-il)metil]amino}-1-piperidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(6,7-Dihidro[1,4]oksatiino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({4-[(6,7-Dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(2,3-dihidro-1H-pirido[3,4-6][1,4]oksazin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(2,3-Dihidro[1,4]oksatiino[2,3-6]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-b]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({4-[(2,3-dihidro[1,4]dioksino[2,3-b]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(1,2,3-benzotiadiazol-5-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(2,3-dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-4-okso-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-9-karbonitrila, Enantiomera E2;
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
9-Fluor-1-[(4-{[(5-okso-1,2,3,5-tetrahidro-7-indolizinil)metil]amino)-1-piperidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(2,3-Dihidro[1,4]oksatiino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E2;
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-6]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E2;
1-({4-[(6,7-Dihidro[1,4]oksatiino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({4-[(6,7-Dihidro[1,4]oksatiino[3,2-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({4-[(6,7-Dihidro-5H-pirano[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
9-Fluor-1-[((3R)-3-{[([1,3]oksatiolo[5,4-c]piridin-6-ilmetil)amino]metil}-1-pirolidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-{[(3R)-3-({[(7-Klor-3-okso-3,4-dihidro-2H-pirido[3,2-b][1,4]oksazin-6-il)metil]amino}metil)-1-pirolidinil]metil}-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
9-Fluor-1-{[(3R)-3-({[(3-okso-3,4-dihidro-2H-pirido[3,2-6][1,4]tiazin-6-il)metil]amino}metil)-1-pirolidinil]metil}-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
9-Fluor-1-{[(3R)-3-({[(3-okso-3,4-dihidro-2H-pirido[3,2-6][1,4]oksazin-6-il)metil]amino}metil)-1-pirolidinil]metil}-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-[((3R)-3-{[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]metil}-1-pirolidinil)metil]-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
9-Fluor-1-[(3-{[([1,3]oksatiolo[5,4-c]piridin-6-ilmetil)amino]metil}-1-pirolidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-{[3-({[(7-Klor-3-okso-3,4-dihidro-2H-pirido[3,2-6][1,4]oksazin-6-il)metil]amino}metil)-1-pirolidinil]metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-{[3-({[(7-Klor-3-okso-3,4-dihidro-2H-pirido[3,2-b][1,4]oksazin-6-il)metil]amino}metil)-1-pirolidinil]metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Izomera 1, 2, 3 ili 4;
1-[(4-{[(3-Okso-3,4-dihidro-2H-pirido[3,2-b][1,4]tiazin-6-il)metil]amino)-1-piperidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[([1,3]Oksatiolo[5,4-c]piridin-6-ilmetil)amino]-1-piperidinil}metil)-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-[(4-{[(7-Klor-3-okso-3,4-dihidro-2H-dihidro[3,2-b][1,4]oksazin-6-il)metil]amino)-1-piperidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(3,4-Dihidro-2H-pirano[2,3-c]piridin-6-ilmetil)amino]-1-piperidinil}metil)-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-[(3-{[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]metil)-1-pirolidinil)metil]-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(6,7-Dihidro[1,4]oksatiino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E2;
9-Fluor-1-{[3-({[(3-okso-3,4-dihidro-2H-pirido[3,2-b][1,4]tiazin-6-il)metil]amino}metil)-1-pirolidinil]metil)-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(6,7-Dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-4-okso-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-9-karbonitrila (Enantiomera E1);
1-({4-[(6,7-Dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-4-okso-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-9-karbonitrila (Enantiomera E2);
1-(R/S)-[(4-{[(3S)-2,3-Dihidro[1,4]dioksino[2,3-b]piridin-3-ilmetil]amino)-1-piperidinil)metil]-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
1-({4-[(6,7-Dihidro-5H-pirano[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-4-okso-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-9-karbonitrila, Enantiomera E1;
1-({4-[(6,7-dihidro-5H-pirano[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
9-Fluor-1-[(4-{[(6-okso-6,7-dihidro-5H-piridazino[3,4-b][1,4]tiazin-3-il)metil]amino)-1-piperidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({4-[(2,3-dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-1-hidroksi-4-okso-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-9-karbonitrila, Enantiomera E1;
1-({4-[(2,3-dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-1-hidroksi-4-okso-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-9-karbonitrila, Enantiomera E2;
1-[(4-{[(7-Klor-3-okso-3,4-dihidro-2H-pirido[3,2-b][1,4]oksazin-6-il)metil]amino)-1-piperidinil)metil]-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-(metiloksi)-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({4-[(2,3-Dihidro[1,4]dioksino[2,3-c]piridin-7-ilmetil)amino]-1-piperidinil}metil)-9-(metiloksi)-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E2;
1-({4-[(6,7-Dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-(metiloksi)-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-on, Enantiomera E1;
9-Fluor-1-{[4-({[(7R/S)-7-(hidroksimetil)-6,7-dihidro[1,4]dioksino[2,3-c]piridazin-3-il]metil}amino)-1-piperidinil]metil)-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Dijastereomera D1;
1-({4-[(5,6-Dihidrofuro[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1;
1-({4-[(5,6-dihidrofuro[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, Enantiomera E1; te
(1R/S)-1-[(4-{[(7S)-6,7-dihidro[1,4]dioksino[2,3-c]piridazin-7-ilmetil]amino)-1-piperidinil)metil]-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona;
ili njihovih farmaceutski prihvatljivih soli i/ili solvata.
11. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 1-({4-[(6,7-dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-on, enantiomer E1, ili njegova farmaceutski prihvatljiva sol i/ili solvat.
12. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je mono 4-metilbenzensulfonatna sol 1-({4-[(6,7-dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, enantiomera E1.
13. Spoj u skladu s patentnim zahtjevom 11, naznačen time što je Mono (2E)-2-butendioatna sol 1-({4-[(6,7-dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, enantiomera E1.
14. Spoj u skladu s patentnim zahtjevom 13, naznačen time što je anhidrat I Mono (2E)-2-butendioatne soli 1-({4-[(6,7-dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, enantiomera E1.
15. Spoj u skladu s patentnim zahtjevom 13, naznačen time što je trihidrat Mono (2E)-2-butendioatne soli 1-({4-[(6,7-dihidro[1,4]dioksino[2,3-c]piridazin-3-ilmetil)amino]-1-piperidinil}metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, enantiomera E1.
16. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 10 ili 12 do 15, naznačen time što je namijenjen upotrebi u liječenju bakterijskih infekcija kod sisavaca.
17. Spoj u skladu s patentnim zahtjevom 11, naznačen time što je namijenjen upotrebi u liječenju bakterijskih infekcija kod sisavaca.
18. Spoj u skladu s patentnim zahtjevom 17, naznačen time što je namijenjen upotrebi u liječenju bakterijskih infekcija kod sisavaca, gdje bakterijsku infekciju uzrokuje gram pozitivni organizam, kojeg se bira između bakterija Staphilococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis i Enterococcus faecium, ili gram negativni organizam, kojeg se bira iz skupine koju čine Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Legionella pneumophila, Chlamydia pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae i Stenotrophomonas maltophilia.
19. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10 ili 12 do 15 i farmaceutski prihvatljivu podlogu.
20. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 11 i farmaceutski prihvatljivu podlogu.
21. Spoj formule (IIB)
[image]
naznačen time što R20 je vodik, a R2' je R2 ili skupina koju se može prevesti u njega, gdje A, R1a, R1b, R2 i R9 su kao što je definirano u patentnom zahtjevu 1.
22. Spoj u skladu s patentnim zahtjevom 21, naznačen time što ga se bira između
1-[(4-Amino-1-piperidinil)metil]-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, enantiomera E1,
1-[(4-Amino-1-piperidinil)metil]-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona, enantiomera E2,
1-{[(3R,4S)-4-amino-3-hidroksi-1-piperidinil]metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona,
1-[(4-Amino-1-piperidinil)metil]-9-fluor-1-hidroksi-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona,
1-{[(3R)-3-(Aminometil)-1-pirohdinil]metil)-9-fluor-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona,
1-[(4-Amino-1-piperidinil)metil]-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-4-ona,
1-[(4-Amino-1-piperidinil)metil]-4-okso-1,2-dihidro-4H-pirolo[3,2,1-ij]kinolin-9-karbonitrila, te
1-[(4-Amino-1-piperidinil)metil]-9-(metiloksi)-1,2-dihidro-4-H-pirolo[3,2,1-ij]kinolin-4-ona.
23. Spoj, naznačen time što je 6,7-dihidro[1,4]dioksino[2,3-c]piridazin-3-karbaldehid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72897505P | 2005-10-21 | 2005-10-21 | |
US82659006P | 2006-09-22 | 2006-09-22 | |
PCT/US2006/060023 WO2007081597A2 (en) | 2005-10-21 | 2006-10-17 | Peri condensed tricyclic compounds useful as antibacterial agents |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20100194T1 true HRP20100194T1 (hr) | 2010-05-31 |
HRP20100194T8 HRP20100194T8 (hr) | 2010-06-30 |
Family
ID=38256822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100194T HRP20100194T8 (hr) | 2005-10-21 | 2010-04-07 | Perikondenzirani triciklički spojevi, korisni kao antibakterijska sredstva |
Country Status (27)
Country | Link |
---|---|
US (2) | US20080280892A1 (hr) |
EP (1) | EP1954697B1 (hr) |
JP (1) | JP2009512695A (hr) |
KR (1) | KR20080064173A (hr) |
AR (1) | AR057981A1 (hr) |
AT (1) | ATE458737T1 (hr) |
AU (1) | AU2006335042A1 (hr) |
BR (1) | BRPI0617467A2 (hr) |
CA (1) | CA2626641A1 (hr) |
CR (1) | CR9930A (hr) |
CY (1) | CY1110137T1 (hr) |
DE (1) | DE602006012535D1 (hr) |
DK (1) | DK1954697T3 (hr) |
EA (1) | EA200801128A1 (hr) |
ES (1) | ES2340531T3 (hr) |
HK (1) | HK1118546A1 (hr) |
HR (1) | HRP20100194T8 (hr) |
IL (1) | IL190803A0 (hr) |
MA (1) | MA29873B1 (hr) |
NO (1) | NO20082191L (hr) |
NZ (1) | NZ567315A (hr) |
PE (1) | PE20070793A1 (hr) |
PL (1) | PL1954697T3 (hr) |
PT (1) | PT1954697E (hr) |
SI (1) | SI1954697T1 (hr) |
TW (1) | TW200736263A (hr) |
WO (1) | WO2007081597A2 (hr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2340531T3 (es) * | 2005-10-21 | 2010-06-04 | Glaxo Group Limited | Compuestos triciclos peri-condensados utiles como agentes antibacterianos. |
DE602006013878D1 (de) | 2005-12-22 | 2010-06-02 | Glaxo Group Ltd | Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel |
WO2007115947A1 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
GB0608263D0 (en) | 2006-04-26 | 2006-06-07 | Glaxo Group Ltd | Compounds |
GB0613208D0 (en) * | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
GB0705672D0 (en) * | 2007-03-23 | 2007-05-02 | Glaxo Group Ltd | Compounds |
CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
AU2008240764C1 (en) * | 2007-04-20 | 2011-10-20 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
GB0707706D0 (en) * | 2007-04-20 | 2007-05-30 | Glaxo Group Ltd | Compounds |
EP2005995A1 (en) * | 2007-06-22 | 2008-12-24 | Glaxo Group Limited | Heterocyclic compounds for the treatment of tuberculosis |
EP2080761A1 (en) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Compounds |
MX2010008922A (es) | 2008-02-20 | 2010-09-07 | Actelion Pharmaceuticals Ltd | Compuestos antibioticos azatriciclicos. |
TW200944529A (en) | 2008-04-15 | 2009-11-01 | Actelion Pharmaceuticals Ltd | Tricyclic antibiotics |
MX2011000968A (es) | 2008-08-04 | 2011-03-02 | Actelion Pharmaceuticals Ltd | Derivados de alquilaminometiloxazolidinona triciclicos. |
BRPI0920895A8 (pt) | 2008-10-07 | 2017-12-26 | Actelion Pharmaceuticals Ltd | Compostos antibióticos de oxazolidinona tricíclica |
WO2010043714A1 (en) | 2008-10-17 | 2010-04-22 | Glaxo Group Limited | Tricyclic nitrogen compounds used as antibacterials |
ES2435596T3 (es) | 2008-12-12 | 2013-12-20 | Actelion Pharmaceuticals Ltd. | Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano |
EP2379554B1 (en) | 2009-01-15 | 2015-11-11 | Glaxo Group Limited | Naphthyridin-2(1h)-one compounds useful as antibacterials |
AR087875A1 (es) | 2011-09-16 | 2014-04-23 | Actelion Pharmaceuticals Ltd | Proceso para la elaboracion de derivados de piridazina como intermediarios de sintesis de antibioticos |
JP2014533747A (ja) | 2011-11-30 | 2014-12-15 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 3,7−二置換オクタヒドロ−2H−ピリド[4,3−e][1,3]オキサジン−2−オン抗生物質 |
EA031589B1 (ru) | 2014-08-22 | 2019-01-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae |
JP6772364B2 (ja) | 2017-02-28 | 2020-10-21 | 三井化学アグロ株式会社 | 植物病害防除組成物およびそれを施用する植物病害の防除方法 |
KR20200003915A (ko) * | 2017-05-10 | 2020-01-10 | 알바후나 테라퓨틱스, 에스.엘. | 높은 이중 HIV 항바이러스 활성과 면역조절 활성을 갖는 Fc-융합 단백질 유도체 |
US20230116403A1 (en) | 2019-12-02 | 2023-04-13 | Storm Therapeutics Limited | Polyheterocyclic compounds as mettl3 inhibitors |
TW202128675A (zh) | 2019-12-06 | 2021-08-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑之經取代四氫呋喃 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3323868A (en) * | 1961-12-14 | 1967-06-06 | Laporte Chemical | Manufacture of hydrogen peroxide |
BE634031A (hr) * | 1962-06-23 | |||
GB1394373A (en) * | 1972-05-17 | 1975-05-14 | Pfizer Ltd | Control of plant diseases |
US4066706A (en) * | 1975-04-21 | 1978-01-03 | Halcon International, Inc. | Preparation of ethylbenzene hydroperoxide |
DE2805915C3 (de) * | 1978-02-13 | 1981-11-05 | Dynamit Nobel Ag, 5210 Troisdorf | Reaktor zur Oxidation von Gemischen aus p-Xylol und p-Toluylsäuremethylester mit sauerstoffhaltigen Gasen in flüssiger Phase |
DE2914218C2 (de) * | 1978-04-12 | 1985-10-24 | Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo | N-Acylderivate des Ampicillins und Amoxicillins, Verfahren zu deren Herstellung und pharmazeutische Zubereitungen, welche die Verbindungen enthalten |
US4416884A (en) * | 1978-04-12 | 1983-11-22 | Otsuka Pharmaceutical Co., Ltd. | Piperazinylbenzoheterocyclic compounds |
NO156828C (no) * | 1980-11-10 | 1987-12-02 | Otsuka Pharma Co Ltd | Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser. |
ATE21514T1 (de) * | 1982-03-25 | 1986-09-15 | Ciba Geigy Ag | Verfahren zur herstellung von 1,2,5,6-tetrahydro4h-pyrrolo(3,2,1-ij)-chinolin-4-on und neue 5ch820325 |
US4595755A (en) * | 1982-03-25 | 1986-06-17 | Ciba-Geigy Corporation | 5-halo-1,2,3-(1,2-dihydropyrrolo)-4-quinolones |
US4603199A (en) * | 1982-10-25 | 1986-07-29 | Riker Laboratories, Inc. | Phenyl-substituted tricyclic antibacterial agent intermediates |
US4443447A (en) * | 1982-10-25 | 1984-04-17 | Riker Laboratories, Inc. | Phenyl-substituted tricyclic antibacterial agents |
US6121285A (en) * | 1995-11-22 | 2000-09-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted aminocycloalkylpyrrolidine derivatives and cis-substituted aminocycloalkylpyrrolidine derivatives |
GB9622386D0 (en) * | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
JPH11222407A (ja) * | 1997-11-14 | 1999-08-17 | Sankyo Co Ltd | 新規殺菌剤 |
US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
US6689765B2 (en) * | 1999-05-04 | 2004-02-10 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
US6289745B1 (en) * | 1999-05-04 | 2001-09-18 | James Bowers | High temperature insertion type flow element and mounting extension |
US7825121B2 (en) * | 1999-05-04 | 2010-11-02 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
GB0101577D0 (en) * | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
UY27192A1 (es) * | 2001-03-01 | 2002-09-30 | Smithkline Beecham Corp | Inhibidores de peptido-deformilasa |
GB0112836D0 (en) * | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
WO2003064431A2 (en) * | 2002-01-29 | 2003-08-07 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
AR040336A1 (es) * | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
AR042486A1 (es) | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
CN1997642B (zh) * | 2003-09-22 | 2012-06-13 | 詹森药业有限公司 | 7-氨基亚烷基-杂环喹诺酮类和萘啶酮类 |
EP1796466A4 (en) * | 2004-06-15 | 2009-09-02 | Glaxo Group Ltd | ANTIBACTERIAL AGENTS |
US20070254872A1 (en) * | 2004-07-08 | 2007-11-01 | Glaxo Group Limited | Antibacterial Agents |
US7732612B2 (en) * | 2004-09-09 | 2010-06-08 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
MY150958A (en) * | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
WO2006137485A1 (ja) * | 2005-06-24 | 2006-12-28 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
DE102005050892A1 (de) * | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
ES2340531T3 (es) * | 2005-10-21 | 2010-06-04 | Glaxo Group Limited | Compuestos triciclos peri-condensados utiles como agentes antibacterianos. |
GB0521563D0 (en) * | 2005-10-21 | 2005-11-30 | Glaxo Group Ltd | Novel compounds |
DE602006013878D1 (de) * | 2005-12-22 | 2010-06-02 | Glaxo Group Ltd | Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel |
WO2007115947A1 (en) * | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
GB0608263D0 (en) * | 2006-04-26 | 2006-06-07 | Glaxo Group Ltd | Compounds |
JP5171618B2 (ja) * | 2006-05-26 | 2013-03-27 | 富山化学工業株式会社 | 新規な複素環化合物またはその塩ならびにその中間体 |
GB0613208D0 (en) * | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
EP1992628A1 (en) * | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
GB0705672D0 (en) * | 2007-03-23 | 2007-05-02 | Glaxo Group Ltd | Compounds |
EP1980251A1 (en) * | 2007-04-13 | 2008-10-15 | Glaxo Group Limited | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis |
AU2008240764C1 (en) * | 2007-04-20 | 2011-10-20 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
GB0707708D0 (en) * | 2007-04-20 | 2007-05-30 | Glaxo Group Ltd | Compounds |
GB0707706D0 (en) * | 2007-04-20 | 2007-05-30 | Glaxo Group Ltd | Compounds |
-
2006
- 2006-10-17 ES ES06849235T patent/ES2340531T3/es active Active
- 2006-10-17 AT AT06849235T patent/ATE458737T1/de active
- 2006-10-17 PT PT06849235T patent/PT1954697E/pt unknown
- 2006-10-17 CA CA002626641A patent/CA2626641A1/en not_active Abandoned
- 2006-10-17 WO PCT/US2006/060023 patent/WO2007081597A2/en active Application Filing
- 2006-10-17 PL PL06849235T patent/PL1954697T3/pl unknown
- 2006-10-17 JP JP2008536625A patent/JP2009512695A/ja active Pending
- 2006-10-17 NZ NZ567315A patent/NZ567315A/en unknown
- 2006-10-17 EA EA200801128A patent/EA200801128A1/xx unknown
- 2006-10-17 DK DK06849235.4T patent/DK1954697T3/da active
- 2006-10-17 KR KR1020087012082A patent/KR20080064173A/ko not_active Application Discontinuation
- 2006-10-17 AU AU2006335042A patent/AU2006335042A1/en not_active Abandoned
- 2006-10-17 EP EP06849235A patent/EP1954697B1/en active Active
- 2006-10-17 US US12/090,947 patent/US20080280892A1/en not_active Abandoned
- 2006-10-17 SI SI200630624T patent/SI1954697T1/sl unknown
- 2006-10-17 BR BRPI0617467-1A patent/BRPI0617467A2/pt not_active IP Right Cessation
- 2006-10-17 US US11/550,005 patent/US20080221110A1/en not_active Abandoned
- 2006-10-17 DE DE602006012535T patent/DE602006012535D1/de active Active
- 2006-10-19 PE PE2006001266A patent/PE20070793A1/es not_active Application Discontinuation
- 2006-10-19 TW TW095138495A patent/TW200736263A/zh unknown
- 2006-10-19 AR ARP060104571A patent/AR057981A1/es not_active Application Discontinuation
-
2008
- 2008-04-10 IL IL190803A patent/IL190803A0/en unknown
- 2008-04-15 MA MA30851A patent/MA29873B1/fr unknown
- 2008-04-25 CR CR9930A patent/CR9930A/es not_active Application Discontinuation
- 2008-05-13 NO NO20082191A patent/NO20082191L/no not_active Application Discontinuation
- 2008-09-10 HK HK08110046.5A patent/HK1118546A1/xx not_active IP Right Cessation
-
2010
- 2010-04-07 HR HR20100194T patent/HRP20100194T8/hr unknown
- 2010-05-10 CY CY20101100405T patent/CY1110137T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AR057981A1 (es) | 2008-01-09 |
SI1954697T1 (sl) | 2010-05-31 |
DE602006012535D1 (de) | 2010-04-08 |
NO20082191L (no) | 2008-07-16 |
PT1954697E (pt) | 2010-05-17 |
EP1954697B1 (en) | 2010-02-24 |
CA2626641A1 (en) | 2007-07-19 |
KR20080064173A (ko) | 2008-07-08 |
TW200736263A (en) | 2007-10-01 |
MA29873B1 (fr) | 2008-10-03 |
AU2006335042A1 (en) | 2007-07-19 |
BRPI0617467A2 (pt) | 2011-07-26 |
US20080280892A1 (en) | 2008-11-13 |
PE20070793A1 (es) | 2007-08-23 |
ES2340531T3 (es) | 2010-06-04 |
ATE458737T1 (de) | 2010-03-15 |
NZ567315A (en) | 2011-01-28 |
EP1954697A2 (en) | 2008-08-13 |
WO2007081597A3 (en) | 2008-06-12 |
CR9930A (es) | 2008-07-29 |
IL190803A0 (en) | 2008-12-29 |
EA200801128A1 (ru) | 2008-10-30 |
JP2009512695A (ja) | 2009-03-26 |
HRP20100194T8 (hr) | 2010-06-30 |
CY1110137T1 (el) | 2015-01-14 |
HK1118546A1 (en) | 2009-02-13 |
US20080221110A1 (en) | 2008-09-11 |
DK1954697T3 (da) | 2010-06-14 |
PL1954697T3 (pl) | 2010-07-30 |
WO2007081597A2 (en) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100194T1 (hr) | Perikondenzirani triciklički spojevi, korisni kao antibakterijska sredstva | |
HRP20100574T1 (hr) | Tricklički spojevi s dušikom kao antibakterijska sredstva | |
US11229646B2 (en) | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | |
Kuhlmann et al. | Quinolone antibacterials | |
ES2353631T3 (es) | Derivados de pirrolo [3,2,1-ij]quinolina-4-ona para tratar la tuberculosis. | |
IE58966B1 (en) | Substituted bridged-diazabicycloalkyl quinolone carboxylic acids | |
JP2010524884A5 (hr) | ||
RU2015131148A (ru) | СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ | |
WO2006081179A1 (en) | Antibacterial agents | |
WO2013042035A4 (en) | Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections | |
US20110009394A1 (en) | Tricyclic nitrogen compounds and their use as antibacterial agents | |
EP2352734A1 (en) | Tricyclic nitrogen compounds used as antibacterials | |
ES2351377T3 (es) | Compuestos tricíclicos que contienen nitrógeno como agentes antibacterianos. |